Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

Khadijah BasheerOphthalmology Department, Central Middlesex Hospital, London, UKCorrespondence[email protected]

Evelyn MensahOphthalmology Department, Central Middlesex Hospital, London, UK

Tina KhanamOphthalmology Department, Central Middlesex Hospital, London, UK

Neda MinakaranOphthalmology Department, Central Middlesex Hospital, London, UK

Pages 959-965 | Published online: 28 May 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BresslerNMBresslerSBCongdonNGPotential public health impact of Age-Related Eye Disease Study results: AREDS report no 11Arch Ophthalmol20031211621162414609922
PubMed Web of Science ®Google Scholar
rcophth.ac.uk [homepage on the Internet]LondonThe Royal College of Ophthalmologists2009 [cited 2013]. Available from: http://www.rcophth.ac.ukAccessed April 17, 2014
Google Scholar
BrownDMRegilloCDAnti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patientsAm J Ophthalmol2007144462763717893015
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJRanibizumab for Neovascular Age-Related Macular DegenerationN Engl J Med20063551419143117021318
PubMed Web of Science ®Google Scholar
BrownDMMichelsMKaiserPKRanibizumab versus verteporfin photodynamic therapy for neovascular ade-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology20091161576519118696
PubMed Web of Science ®Google Scholar
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
PubMed Web of Science ®Google Scholar
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related maculuar degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
PubMed Web of Science ®Google Scholar
MałgorzataFStankiewiczAEffectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomesMed Sci Monit2011179CR48549021873944
PubMed Web of Science ®Google Scholar
ShienbaumGGarcia FilhoCAFlynnHWJrNunesRPSmiddyWERosenfeldPJManagement of submacular hemorrage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapyAm J Ophthalmol201315561009101323465269
PubMed Web of Science ®Google Scholar
CohenSYDuboisLTadayoniRResults of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical settingAm J Ophthalmol2009148340941319477713
PubMed Web of Science ®Google Scholar
DadgostarHVenturaAAChungJYSharmaSKaiserPKEvaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degenerationOphthalmology200911691740174719643484
PubMed Web of Science ®Google Scholar
QuerquesGAzryaSMartinelliDRanibizumab for exudative age-related macular degeneration: 24 month outcomes from a single centre institutional settingBr J Ophthalmol201094329229619951942
PubMed Web of Science ®Google Scholar
BandukwalaTMuniRHSchwartzCEngKTKertesPJEffectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective reviewCan J Ophthalmol201045659059521135894
PubMed Web of Science ®Google Scholar
KangSRohYJOne-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroupsJpn J Ophthalmol200953438939519763757
PubMed Web of Science ®Google Scholar
SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)2010241708171520885427
PubMed Web of Science ®Google Scholar
HjelmqvistLLindbergCKanulfPDahlgrenHJohanssonISiewertAOne-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrispective observational multicentre studyJ Ophthalmol2011201140572422174994
PubMed Web of Science ®Google Scholar
FengXFConstableIJMcAllisterILIsaacsTComparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degenerationInt J Ophthalmol201141858822553617
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date